<DOC>
	<DOCNO>NCT00297674</DOCNO>
	<brief_summary>The aim clinical trial clarify clinical efficacy clarithromycin immunotherapy management septic syndrome ventilator-associated pneumonia .</brief_summary>
	<brief_title>Intravenous Clarithromycin Septic Syndrome</brief_title>
	<detailed_description>The rationale trial base favorable result experimental study sepsis multidrug-resistant Pseudomonas aeruginosa susceptible Escherichia coli rabbit clarithromycin administer intravenously . Data latter study suggest administration clarithromycin extend survival attenuate systemic inflammatory response . Their major endpoint successful immunotherapy achieve clarithromycin administer presentation symptom sepsis-induced pulmonary edema ; contrary , former clinical trial immunotherapy sepsis base animal study evolution immunomodulator administer bacterial challenge . The efficacy administration clarithromycin upon presentation septic syndrome animal study , render application promise clinical field .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>1. write informed consent provide first second degree relative ; 2. intubation mechanical ventilation least 48 hour prior enrolment ; c ) age patient equal 18 year ; ) diagnosis Ventilator Associated Pneumonia ; e ) sign sepsis 1. neutropenia , define less 500 neutrophils/mm3 ; 2 . HIV infection ; 3. oral intake corticosteroid dose equal high 1mg/kg equivalent prednisone period great one month ; 4. administration drotrecogin alpha last five day prior enrolment ; e ) atrioventricular block second third degree .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>clarithromycin</keyword>
	<keyword>sepsis</keyword>
	<keyword>immunomodulation</keyword>
</DOC>